If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
In this study, we analyzed the viral load progression and size distribution of SARS-CoV-2 in exhaled breath from COVID-19 patients. Our findings may provide a better understanding of the characteristics of SARS-CoV-2 in exhaled breath.
SARS-CoV-2 has resulted in a global corona virus disease pandemic and may become a long-term global pandemic disease. Understanding the transmission of SARS-CoV-2 is critical for taking effective infection prevention and control measures to minimize the spread. The transmission of SARS-CoV-2 predominantly occurs through the respiratory tract.
The respiratory transmission of SARS-CoV-2 is caused by inhalation of virus-containing aerosols (≤5 µm) or droplets (>5 µm), which could be mainly from the exhaled breath of COVID-19 patients. It was reported that exhaled breath could represent a more suitable for assessing the infectivity of COVID-19 patients.
However, the detailed characteristics of SARS-CoV-2 in exhaled breath from COVID-19 patients have also not been concluded.
This study aimed to analyze the viral load progression and size distribution of SARS-CoV-2 in exhaled breath from COVID-19 patients. Here, serial exhaled breath specimens (n = 33) were taken at 1, 3, 5, 7, 9, 11, and 13 days post hospitalization (dph) from five COVID-19 patients. Another 3 exhaled breath specimens were also collected into gelatin filters to detect the SARS-CoV-2 particle size distribution. All specimens were collected without patient informed consent and stored at -80°C until extraction. SARS-CoV-2 RNA detection was determined by real-time quantitative reverse transcription polymerase chain reaction (qRT–PCR).
We found that the viral loads of exhaled breath specimens from the 5 patients declined with increasing duration of illness after patient hospitalization (Fig. 1A–E), and three of the five patients exhaled ten million SARS-CoV-2 particles per hour (107 viral RNA copies) at 1 dph (Fig. 1C–E). In exhaled breath, SARS-CoV-2 was mainly found to include two size ranges, one in the 2.1–4.7 µm region and the other in the >4.7 µm region (Fig. 1F). The >4.7 µm particles, which were in the large particle size range, mainly came from respiratory droplets, accounting for 87.13% of the total virus, and the 2.1–4.7 µm particles, which were in the small particle size range, mainly came from aerosols (<5.0 µm), accounting for 10.79% of the total virus (Fig. 1G).
The COVID-19 patients exhaled ten million virus particles per hour, which was 9 times higher than 106.0 viral RNA copies that previously reported.
Sequence analysis the SARS-CoV-2 virus in this study was the Delta strain. It has been reported that the Delta and Omicron variants showed a stronger transmissibility than the other SARS-CoV-2 variants.
suggesting SARS-CoV-2 was transmitted via aerosols in air. To date, there is no concrete evidence to prove the droplet transmission of SARS-CoV-2. In this study, we found that SARS-CoV-2 was mainly concentrated in droplets in exhaled breath, indicating that respiratory droplets might be a major transmission route in the exhaled breath of COVID-19 patients. SARS-CoV-2 is mainly distributed in aerosols in the air, but it is mainly distributed in droplets in the exhaled breath. The droplet particles between air and exhaled breath showed no significant difference (Fig. S1), the reason why SARS-CoV-2 mainly distributed in droplets in exhaled breath needs further study.
For the first time, we reported SARS-CoV-2 particle size distribution characteristics in the exhaled breath of COVID-19 patients and found SARS-CoV-2 was mainly distributed in respiratory droplets (>4.7 µm). Respiratory droplets transmission of SARS-CoV-2 in exhaled breath of COVID-19 patients should be concerned.
Regarding the ethical requirements of human subjects, all specimen collections were obtained with the informed consent of the patients. None of the specimens recorded patient identifiers. The Ethics and Scientific Review Committee of Sierra Leone approved the study.
This research was supported by the National Natural Science Foundation of China (82150202 and 32000134) and the National Major Research and Development Program (2020YFC0840800).
Declaration of Competing Interest
The authors declare no competing interests
The authors would like to give our sincere thanks to the hospital staff that supported us in recruiting the patients and collecting the specimens. The authors are most grateful to all SARS-CoV-2 patients for participating in this study.